Mouthon Luc
Service de médecine interne, hôpital Cochin, 75679 Paris Cedex 14.
Rev Prat. 2005 May 31;55(10):1049-56.
Intravenous immunoglobulins (IVIg) are therapeutic preparations of normal human IgG that are obtained from pools of healthy blood donors. They can be used at low dose in the substitutive therapy of patients with primary or secondary immune deficiencies, or at high dose as an immunomodulatory agent in a large number of autoimmune and/or systemic inflammatory diseases, particularly in hematologic or neurologic diseases. Tolerance to IVIg is excellent in most of the cases and the risk of transmission of an infectious agent is only theoretical. Mechanisms of action of IVIg are multiple and complicated. The development of new therapeutic trials in association with analyses of mechanisms of action should help to define new indication of IVIg therapy.
静脉注射免疫球蛋白（IVIg）是从健康献血者的血液池中获取的正常人IgG的治疗制剂。它们可低剂量用于原发性或继发性免疫缺陷患者的替代治疗，或高剂量用作多种自身免疫性和/或全身性炎症性疾病的免疫调节剂，特别是在血液学或神经学疾病中。在大多数情况下，对IVIg的耐受性良好，感染因子传播的风险仅为理论上的。IVIg的作用机制多种多样且复杂。结合作用机制分析开展新的治疗试验，应有助于明确IVIg治疗的新适应症。
